-

12:57:08 PM

IONS Stock News

IONS - Ionis Pharmaceuticals Inc

11/24/21 6:30 AM

Nasdaq : IONS

clinical trial

Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Pfizer has provided an update on the Phase 2b study of vupanorsen, formerly IONIS-ANGPTL3-L Rx. Vupanorsen is an investigational antisense therapy being developed for indications in

RHEA-AI

neutral

11/18/21 1:30 PM

Nasdaq : IONS

clinical trial

Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today initiation of OASIS-HAE, the registrational study in the donidalorsen (formerly IONIS-PKK-L Rx) Phase 3 clinical program. Donidalorsen is an

RHEA-AI

neutral

11/12/21 7:05 AM

Nasdaq : IONS

Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today the upcoming presentations of clinical and non-clinical data from its cardiovascular pipeline, including several of its investigational antisense

RHEA-AI

neutral

11/09/21 7:05 AM

Nasdaq : IONS

conferences

Ionis to present at upcoming virtual investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in virtual fireside chats at the following virtual investor conferences:Stifel 2021 Healthcare Conference on Monday, November 15, 2021 Evercore ISI 4 th

RHEA-AI

neutral

11/07/21 7:05 AM

Nasdaq : IONS

clinical trial

Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today that positive results from the Phase 2 study of its investigational antisense medicine, donidalorsen (formerly IONIS-PKK-L Rx), will be presented at the

RHEA-AI

neutral

11/03/21 7:00 AM

Nasdaq : IONS

earnings

Ionis reports third quarter 2021 financial results and recent business achievements

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the three and nine months ended September 30, 2021 and recent business achievements."Among recent business highlights, we further expanded our broad late-stage pipeline

RHEA-AI

neutral

11/02/21 7:05 AM

Nasdaq : IONS

clinical trial

Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today the initiation of CORE, the second Phase 3 clinical study of olezarsen, formerly known as IONIS-APOCIII-L Rx. The CORE study is evaluating olezarsen in

RHEA-AI

neutral

10/20/21 7:05 AM

Nasdaq : IONS

earnings

Ionis to hold third quarter 2021 financial results webcast

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, November 3 rd at 11:30 a.m. Eastern Time to discuss its third quarter 2021 financial results and report on pipeline and business

RHEA-AI

neutral

10/17/21 4:20 PM

Nasdaq : IONS

clinical trial

Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) partner Biogen today announced topline results from its placebo-controlled pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense medicine being evaluated for people with superoxide

RHEA-AI

neutral

09/03/21 7:05 AM

Nasdaq : IONS

conferences

Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today it will present 14 posters and two symposiums highlighting new scientific insights from its ATTR amyloidosis portfolio at the 3 rd European ATTR

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

IONS Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.ionispharma.com
CeoBrett Monia
Security nameIonis Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees757
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address2855 Gazelle Ct
StateCalifornia
CityCarlsbad
Zip92010-6670
CountryUS
Phone17609319200

IONS Description:

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Its scientific innovation began and continues with the knowledge that sick people depend on it, which fuels its vision of becoming one of the most successful biotechnology companies.